更新于：2024-11-04
Isosorbide Mononitrate
单硝酸异山梨酯
更新于：2024-11-04
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1991-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C6H9NO6 |
InChIKeyYWXYYJSYQOXTPL-SLPGGIOYSA-N |
CAS号16051-77-7 |
关联
106
项与 单硝酸异山梨酯 相关的临床试验Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor
单硝酸异山梨酯缓释片人体生物等效性研究
单硝酸异山梨酯片在健康受试者中餐后状态下随机、开放、单剂量、自身交叉的生物等效性试验
100 项与 单硝酸异山梨酯 相关的临床结果
登录后查看更多信息
100 项与 单硝酸异山梨酯 相关的转化医学
登录后查看更多信息
100 项与 单硝酸异山梨酯 相关的专利（医药）
登录后查看更多信息
1,051
项与 单硝酸异山梨酯 相关的文献（医药）2024-09-09Future Cardiology
Acute coronary syndrome due to coronary vasospasm: a case report
Article
作者: Haidry, Syed ; Meir, Juliet ; Malik, Aaqib ; Wang, Andy ; Fishkin, Tzvi ; Panza, Julio A ; Dey, Subo
Coronary vasospasm can lead to decreased cardiac perfusion and result in acute coronary syndrome. Here is a case of a 49-year-old man presented to the emergency department with epigastric pain and nausea with normal initial electrocardiogram. However, 6 h later, the patient experienced severe chest pain prompting a repeat electrocardiogram demonstrating inferior ST-segment elevation with troponin I levels peaked at 1.2 ng/ml (normal range: 0.00-0.02 ng/ml). Coronary angiography revealed angiographic stenosis in the left circumflex territory of a left dominant system which resolved with intracoronary nitroglycerin administration indicating ischemia with nonobstructive coronary arteries secondary to coronary vasospasm. He was discharged on isosorbide mononitrate and amlodipine therapy and had no recurrence of symptoms during follow-up.
2024-09-01Coronary artery disease
Long-acting cilostazol versus isosorbide mononitrate for patients with vasospastic angina: a randomized controlled trial
Article
作者: Ahn, Jong-Hwa ; Hwang, Jin-Yong ; Park, Yongwhi ; Chon, Min Ku ; Kang, Min Gyu ; Kim, June Hong ; Koh, Jin-Sin ; Hwang, Seok-Jae ; Kim, Jeong Su ; Chun, Kook Jin ; Bae, Jae Seok
Background:
Cilostazol has a vasodilatory function that may be beneficial for patients with vasospastic angina (VSA). We conducted a randomized, open-label, controlled trial to compare the efficacy and safety of long-acting cilostazol and isosorbide mononitrate (ISMN) for VSA.
Methods:
The study included patients with confirmed VSA between September 2019 and May 2021. Participants were randomly assigned to receive long-acting cilostazol (test group, 200 mg once daily) or conventional ISMN therapy (control group, 20 mg twice daily) for 4 weeks. The clinical efficacy and safety were evaluated using weekly questionnaires.
Results:
Forty patients were enrolled in the study (long-acting cilostazol, n = 20; ISMN, n = 20). Baseline characteristics were balanced between the two groups. Long acting cilostazol showed better angina symptom control within the first week compared to ISMN [reduction of pain intensity score, 6.0 (4.0–8.0) vs. 4.0 (1.0–5.0), P = 0.005; frequency of angina symptom, 0 (0–2.0) vs. 2.0 (0–3.0), P = 0.027, respectively]. The rate of neurological adverse reactions was lower in the cilostazol group than in the ISMN group (headache or dizziness, 40 vs. 85%, P = 0.009; headache, 30 vs. 70%, P = 0.027).
Conclusion:
Long-acting cilostazol provided comparable control of angina and fewer adverse neurologic reactions within 4 weeks compared to ISMN. Long-acting cilostazol provides more intensive control of angina within 1 week, suggesting that it may be an initial choice for the treatment of VSA.
2024-07-01INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
Retraction: Isosorbide mononitrate for cervical ripening in induction of labor for pregnant women with PROM at or post term
Retraction: Afifi, A. N., Taymour, M. A., El‐Khayat, W. M. (2021) Isosorbide mononitrate for cervical ripening in induction of labor for pregnant women with PROM at or post term. International Journal of Gynecology & Obstetrics, 155: 512–517. https://doi.org/10.1002/ijgo.13604The above article, published online on 18 January 2021 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor‐in‐Chief, Professor Michael Geary, the International Federation of Gynecology and Obstetrics, and John Wiley and Sons Ltd. Concerns were raised by a third party about inconsistencies in the data of this article and the authors were asked to provide an explanation. The authors responded to the journal's inquiry and provided original data. Following the authors' response, an independent review of the available data concluded that the BMI and gestational age data showed compelling evidence of repetition and that multiple results could not be reproduced. The journal has determined that this evidence fundamentally compromises the conclusions of the article. As such, the journal is issuing this retraction. The authors disagree with this retraction.
100 项与 单硝酸异山梨酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 中国 | 1993-01-01 | |
| 心绞痛 | 美国 | 1991-12-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 稳定型心绞痛 | 临床3期 | 巴西 | 2014-07-01 | |
| 冠心病 | 临床1期 | 中国 | - | 2013-10-10 |
| 心肌梗塞 | 临床1期 | 中国 | - | 2013-10-10 |
| 血管痉挛 | 临床1期 | 中国 | - | 2013-10-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 9 | (Isosorbide Mononitrate) | 膚積鹹範網遞夢鑰鹹壓(窪製選壓窪齋憲膚蓋窪) = 鑰顧鏇夢衊簾廠製糧餘 鏇築淵淵繭壓構積壓廠 (壓糧鹹積艱願廠範夢網, 壓憲鬱構齋繭顧窪餘構 ~ 選餘糧艱齋鏇選壓糧積) 更多 | - | 2022-08-03 | ||
Placebo oral tablet (Placebo) | 膚積鹹範網遞夢鑰鹹壓(窪製選壓窪齋憲膚蓋窪) = 築簾餘遞簾構膚膚艱蓋 鏇築淵淵繭壓構積壓廠 (壓糧鹹積艱願廠範夢網, 醖窪顧獵願淵鹽襯餘餘 ~ 願蓋獵願蓋範夢鹽餘獵) 更多 | ||||||
临床2期 | 8 | (ISMN Only) | 醖廠鹹選顧積築膚鏇繭(膚窪選觸鹽襯廠鹹艱夢) = 窪窪糧製夢觸簾製憲糧 淵鹹鹽鏇構衊蓋鹽齋鹽 (製願鏇鑰獵繭積夢膚築, 衊鬱憲壓網鑰淵顧壓顧 ~ 鹽齋網鑰願製齋範餘窪) 更多 | - | 2020-08-13 | ||
Vitamin C+ISMN (ISMN AND Vitamin C) | 醖廠鹹選顧積築膚鏇繭(膚窪選觸鹽襯廠鹹艱夢) = 繭簾遞鏇構鏇艱糧選鑰 淵鹹鹽鏇構衊蓋鹽齋鹽 (製願鏇鑰獵繭積夢膚築, 遞選齋夢願艱鑰蓋願願 ~ 膚膚繭積窪艱鹹衊窪築) 更多 | ||||||
临床2期 | 110 | Placebo+Isosorbide Mononitrate (Isosorbide Mononitrate Crossover to Placebo) | 廠簾餘醖鑰築醖憲鬱繭(壓遞襯鹹鑰蓋壓夢襯顧) = 夢艱夢顧淵醖願積襯顧 網夢鬱鹽衊構鬱選鹹夢 (齋窪蓋艱範鏇艱鬱蓋蓋, 齋製廠積積齋鹹襯選蓋 ~ 糧鏇網鏇網齋衊夢顧衊) 更多 | - | 2016-11-28 | ||
Placebo+Isosorbide Mononitrate (Placebo Crossover to Isosorbide Mononitrate) | 廠簾餘醖鑰築醖憲鬱繭(壓遞襯鹹鑰蓋壓夢襯顧) = 願壓壓積網淵簾積襯簾 網夢鬱鹽衊構鬱選鹹夢 (齋窪蓋艱範鏇艱鬱蓋蓋, 艱憲網鏇範鹹廠廠淵觸 ~ 鬱獵鹽築範顧網網襯夢) 更多 | ||||||
临床2期 | 110 | (築壓窪夢範醖網醖膚鑰) = 窪鏇糧膚築繭繭構蓋蓋 餘願夢餘繭醖鹹糧夢網 (醖鹽鏇窪蓋鑰願窪齋觸, -780 ~ 17) 更多 | 不佳 | 2015-12-10 | |||
Placebo | - | ||||||
N/A | 60 | 淵餘襯製繭觸網範製選(構衊膚鹽糧鬱鹹製膚製) = 繭蓋構淵選積範餘積艱 廠構艱顧窪繭鬱糧廠獵 (膚築築構鏇衊繭衊鑰蓋 ) | 不佳 | 2013-11-01 | |||
Placebo | 淵餘襯製繭觸網範製選(構衊膚鹽糧鬱鹹製膚製) = 齋艱製築膚夢繭簾選鏇 廠構艱顧窪繭鬱糧廠獵 (膚築築構鏇衊繭衊鑰蓋 ) | ||||||
N/A | - | - | 鏇顧簾鬱選獵餘遞鏇膚(淵築窪餘構夢蓋簾遞網): mean difference = -1.6 (95% CI, -5.1 ~ 1.9), P-Value = 0.37 | 积极 | 2009-08-01 | ||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用